Cargando…

Tumor-Associated Macrophages Induce Endocrine Therapy Resistance in ER+ Breast Cancer Cells

Antiestrogenic adjuvant treatments are first-line therapies in patients with breast cancer positive for estrogen receptor (ER+). Improvement of their treatment strategies is needed because most patients eventually acquire endocrine resistance and many others are initially refractory to anti-estrogen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castellaro, Andrés M., Rodriguez-Baili, María C., Di Tada, Cecilia E., Gil, Germán A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406935/ https://www.ncbi.nlm.nih.gov/pubmed/30736340 http://dx.doi.org/10.3390/cancers11020189

Ejemplares similares

Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer
por: Bahnassy, Shaymaa, et al.
Publicado: (2023)

ECM1 is associated with endocrine resistance in ER(+) breast cancers
por: Lee, Tae Won, et al.
Publicado: (2022)

The Central Contributions of Breast Cancer Stem Cells in Developing Resistance to Endocrine Therapy in Estrogen Receptor (ER)-Positive Breast Cancer
por: Rodriguez, David, et al.
Publicado: (2019)

PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells
por: Ito, Koichi, et al.
Publicado: (2017)

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations
por: Ladd, Brendon, et al.
Publicado: (2016)

Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer
por: Soleimani Dodaran, Maryam, et al.
Publicado: (2020)

SAT-119 Targeting Glutamate Metabolism and Signaling in ER+, Endocrine Therapy-Resistant Breast Cancer
por: Olukoya, Ayodeji O, et al.
Publicado: (2020)

Oxalate induces breast cancer
por: Castellaro, Andrés M., et al.
Publicado: (2015)

The interaction between ER and NFκB in resistance to endocrine therapy
por: Sas, Leen, et al.
Publicado: (2012)

Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients
por: Paoletti, Costanza, et al.
Publicado: (2021)

Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer
por: Jia, Yan, et al.
Publicado: (2019)

ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation
por: Huggins, Rosemary J., et al.
Publicado: (2023)

ER-positive breast cancer cells are poised for RET-mediated endocrine resistance
por: Horibata, Sachi, et al.
Publicado: (2018)

Hypoxia and ERα Transcriptional Crosstalk Is Associated with Endocrine Resistance in Breast Cancer
por: Jehanno, Charly, et al.
Publicado: (2022)

Automated Quantification of Extranuclear ERα Using Phosphor-Integrated Dots for Predicting Endocrine Therapy Resistance in HR(+)/HER2(−) Breast Cancer
por: Guo, Zhaorong, et al.
Publicado: (2019)

Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer
por: Olukoya, Ayodeji O, et al.
Publicado: (2023)

Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer
por: Belli, Stefania, et al.
Publicado: (2023)

Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer
por: Fox, Emily M., et al.
Publicado: (2012)

Prognostic Significance of High Expression of ER-beta in Surgically Treated ER-Positive Breast Cancer Following Endocrine Therapy
por: Kim, Tae-Jung, et al.
Publicado: (2012)

VAV3 mediates resistance to breast cancer endocrine therapy
por: Aguilar, Helena, et al.
Publicado: (2014)

Aurora-A Mitotic Kinase Induces Endocrine Resistance through Down-Regulation of ERα Expression in Initially ERα+ Breast Cancer Cells
por: Opyrchal, Mateusz, et al.
Publicado: (2014)

Heregulin Drives Endocrine Resistance by Altering IL-8 Expression in ER-Positive Breast Cancer
por: Papadimitropoulou, Adriana, et al.
Publicado: (2020)

AKTIP loss is enriched in ERα-positive breast cancer for tumorigenesis and confers endocrine resistance
por: Ng, Angel S.N., et al.
Publicado: (2022)

Correlation between serum lipid levels and endocrine resistance in patients with ER-positive breast cancer
por: Sun, Hong, et al.
Publicado: (2023)

Pathways to Endocrine Therapy Resistance in Breast Cancer
por: Haque, Md. Moquitul, et al.
Publicado: (2019)

OR16-5 Riluzole suppresses growth and enhances response to endocrine therapy in ER+ breast cancer
por: Bahnassy, Shaymaa, et al.
Publicado: (2022)

Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy
por: Jeong, Hyehyun, et al.
Publicado: (2023)

Inverse relationship between ER-β and SRC-1 predicts outcome in endocrine-resistant breast cancer
por: Myers, E, et al.
Publicado: (2004)

Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance
por: Strillacci, Antonio, et al.
Publicado: (2022)

JMJD6 orchestrates a transcriptional program in favor of endocrine resistance in ER+ breast cancer cells
por: Das, Partha, et al.
Publicado: (2022)

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer
por: Roßwag, Sven, et al.
Publicado: (2021)

The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer
por: Yuan, Jie, et al.
Publicado: (2023)

PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer
por: Rees, Michael, et al.
Publicado: (2020)

Predicting response/resistance to endocrine therapy for breast cancer
por: Miller, WR, et al.
Publicado: (2005)

Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer
por: Attia, Yasmin M., et al.
Publicado: (2020)

An estrogen receptor (ER)‐related signature in predicting prognosis of ER‐positive breast cancer following endocrine treatment
por: Tang, Jianing, et al.
Publicado: (2019)

Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer
por: Haddad, Tufia C., et al.
Publicado: (2017)

The Tumor Microenvironment as a Regulator of Endocrine Resistance in Breast Cancer
por: Diaz Bessone, María Inés, et al.
Publicado: (2019)

Influence of endocrine therapy on the ratio of androgen receptor (AR) to estrogen receptor (ER) positive circulating epithelial tumor cells (CETCs) in breast cancer
por: Pizon, Monika, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ijmplm0vp1i8pb0ol6upalmi3l